Joaquín Mosquera

1.7k total citations
39 papers, 457 citations indexed

About

Joaquín Mosquera is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Joaquín Mosquera has authored 39 papers receiving a total of 457 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 11 papers in Cancer Research. Recurrent topics in Joaquín Mosquera's work include Lung Cancer Treatments and Mutations (15 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Breast Cancer Treatment Studies (7 papers). Joaquín Mosquera is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Breast Cancer Treatment Studies (7 papers). Joaquín Mosquera collaborates with scholars based in Spain, Italy and France. Joaquín Mosquera's co-authors include Ivana Sullivan, Javier de Castro, Luís Antón Aparicio, Luis León‐Mateos, Benigno Acea Nebril, Ernest Nadal, Lourdes Calvo, Óscar Juan, Rosario García‐Campelo and Margarita Amenedo and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Joaquín Mosquera

38 papers receiving 454 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joaquín Mosquera Spain 12 305 226 71 55 53 39 457
J. Madelaine France 10 223 0.7× 208 0.9× 33 0.5× 105 1.9× 41 0.8× 33 406
Yu Miura Japan 17 570 1.9× 380 1.7× 56 0.8× 78 1.4× 72 1.4× 46 748
Mitsumasa Kawago Japan 10 166 0.5× 284 1.3× 62 0.9× 67 1.2× 64 1.2× 28 416
Tomohiro Sakamoto Japan 11 237 0.8× 257 1.1× 78 1.1× 91 1.7× 101 1.9× 47 461
Yuzuru Watanabe Japan 10 165 0.5× 150 0.7× 91 1.3× 58 1.1× 61 1.2× 24 356
Dian Ren China 12 136 0.4× 165 0.7× 76 1.1× 21 0.4× 95 1.8× 26 325
Gemma Bruera Italy 13 329 1.1× 129 0.6× 85 1.2× 30 0.5× 78 1.5× 47 451
Francesca Sperandi Italy 12 346 1.1× 239 1.1× 60 0.8× 46 0.8× 137 2.6× 50 511
Adithya Chennamadhavuni United States 7 344 1.1× 121 0.5× 35 0.5× 16 0.3× 85 1.6× 18 446
Shotaro Kato Japan 5 292 1.0× 136 0.6× 47 0.7× 80 1.5× 51 1.0× 14 418

Countries citing papers authored by Joaquín Mosquera

Since Specialization
Citations

This map shows the geographic impact of Joaquín Mosquera's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joaquín Mosquera with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joaquín Mosquera more than expected).

Fields of papers citing papers by Joaquín Mosquera

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joaquín Mosquera. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joaquín Mosquera. The network helps show where Joaquín Mosquera may publish in the future.

Co-authorship network of co-authors of Joaquín Mosquera

This figure shows the co-authorship network connecting the top 25 collaborators of Joaquín Mosquera. A scholar is included among the top collaborators of Joaquín Mosquera based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joaquín Mosquera. Joaquín Mosquera is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Remón, Jordi, Paolo Bironzo, Nicolas Girard, et al.. (2025). Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial. The Lancet Oncology. 26(9). 1215–1226. 1 indexed citations
2.
Calvo, Virginia, et al.. (2024). 1284P Clinical utility of liquid biopsy for non-small cell lung cancer patients with ALK fusion variants treated with brigatinib. Annals of Oncology. 35. S819–S819. 1 indexed citations
3.
Masip, J. Remon, Paolo Bironzo, N. Girard, et al.. (2024). LBA83 PECATI: A phase II trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced B3-thymoma and thymic carcinoma. Annals of Oncology. 35. S1270–S1270. 3 indexed citations
4.
Galán‐Moya, Eva María, Manuel Fernández-Delgado, Joaquín Mosquera, et al.. (2024). Software BreastAnalyser for the semi-automatic analysis of breast cancer immunohistochemical images. Scientific Reports. 14(1). 2995–2995. 4 indexed citations
5.
Serna‐Blasco, Roberto, Ernest Nadal, J.L. González-Larriba, et al.. (2024). 138P Faecalibacterium prausnitzii enhances tumor response to perioperative nivolumab and chemotherapy. ESMO Open. 9. 102725–102725. 1 indexed citations
6.
Carpintero-Fernández, Paula, et al.. (2024). Insights into the role of connexins and specialized intercellular communication pathways in breast cancer: Mechanisms and applications. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1879(5). 189173–189173. 5 indexed citations
7.
Aix, Santiago Ponce, Enric Carcereny, Joaquim Bosch‐Barrera, et al.. (2021). 160P Pembrolizumab re-challenge in patients with relapsed non-small cell lung cancer (NSCLC): A preliminary report of the REPLAY phase II trial - cohort I. Annals of Oncology. 32. S1450–S1450. 5 indexed citations
8.
Remón, Jordi, Nicolas Girard, Silvia Novello, et al.. (2021). PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients. Clinical Lung Cancer. 23(3). e243–e246. 24 indexed citations
9.
Antolín, Silvia, Lucía García‐Caballero, Joaquín Mosquera, et al.. (2021). Is there a correlation between HER2 gene amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2-positive breast cancer?. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 479(4). 853–857. 12 indexed citations
10.
Riudavets, Mariona, Joaquín Mosquera, Rosario García‐Campelo, et al.. (2020). Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents. Frontiers in Oncology. 10. 1677–1677. 41 indexed citations
11.
Riudavets, Mariona, Joaquín Mosquera, Rosario García Campelo, et al.. (2019). P2.04-52 Impact of Corticosteroids and Antibiotics on Efficacy of Immune-Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(10). S728–S728. 4 indexed citations
12.
Ruiz‐Bañobre, Juan, Joaquín Mosquera, Margarita Amenedo, et al.. (2019). Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy. Translational Lung Cancer Research. 8(6). 1078–1085. 35 indexed citations
13.
Nebril, Benigno Acea, et al.. (2019). Evaluation of MRI accuracy after primary systemic therapy in breast cancer patients considering tumor biology: optimizing the surgical planning. Radiology and Oncology. 53(2). 171–177. 7 indexed citations
14.
Mosquera, Joaquín, et al.. (2019). Impact of corticosteroids and antibiotics on efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer. Annals of Oncology. 30. v525–v525. 4 indexed citations
15.
Mosquera, Joaquín, Jorge García, Margarita Amenedo, et al.. (2018). Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience. Translational Lung Cancer Research. 7(3). 404–415. 45 indexed citations
16.
Campelo, Rosario García, Francisco Javier Barón-López, Patricia Fernández, et al.. (2017). P3.02c-098 An Observational Study of the Efficacy and Safety of Nivolumab in Patients with Advanced NSCLC. A Galician Lung Cancer Group. Journal of Thoracic Oncology. 12(1). S1339–S1340. 2 indexed citations
17.
Nebril, Benigno Acea, et al.. (2016). Factores de riesgo de afectación de los márgenes quirúrgicos en la cirugía conservadora del cáncer de mama tras quimioterapia neoadyuvante. Cirugía Española. 94(7). 379–384. 6 indexed citations
18.
Nebril, Benigno Acea, et al.. (2016). Risk Factors for Positive Margins in Conservative Surgery for Breast Cancer After Neoadjuvant Chemotherapy. Cirugía Española (English Edition). 94(7). 379–384. 4 indexed citations
19.
León‐Mateos, Luis, Joaquín Mosquera, & Luís Antón Aparicio. (2015). Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors. Redox Biology. 6. 421–425. 28 indexed citations
20.
Martínez‐Girón, Rafael, et al.. (2013). Black-pigmented sputum. Journal of Cytology. 30(4). 274–274. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J. Madelaine Breakdown of academic impact, for papers by Yu Miura Breakdown of academic impact, for papers by Mitsumasa Kawago Breakdown of academic impact, for papers by Tomohiro Sakamoto Breakdown of academic impact, for papers by Yuzuru Watanabe Breakdown of academic impact, for papers by Dian Ren Breakdown of academic impact, for papers by Gemma Bruera Breakdown of academic impact, for papers by Francesca Sperandi Breakdown of academic impact, for papers by Adithya Chennamadhavuni Breakdown of academic impact, for papers by Shotaro Kato
Rankless by CCL
2026